A detailed history of Black Rock Inc. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 8,565,317 shares of RVNC stock, worth $22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,565,317
Previous 7,312,479 17.13%
Holding current value
$22 Million
Previous $36 Million 38.82%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.34 - $4.73 $2.93 Million - $5.93 Million
1,252,838 Added 17.13%
8,565,317 $22 Million
Q1 2024

May 10, 2024

SELL
$4.65 - $9.31 $655,147 - $1.31 Million
-140,892 Reduced 1.89%
7,312,479 $36 Million
Q4 2023

Feb 13, 2024

BUY
$5.81 - $11.2 $4.05 Million - $7.8 Million
696,651 Added 10.31%
7,453,371 $65.5 Million
Q3 2023

Nov 13, 2023

BUY
$11.47 - $25.07 $2.64 Million - $5.77 Million
230,132 Added 3.53%
6,756,720 $77.5 Million
Q2 2023

Aug 11, 2023

BUY
$24.7 - $37.61 $9.57 Million - $14.6 Million
387,524 Added 6.31%
6,526,588 $165 Million
Q1 2023

May 12, 2023

SELL
$18.36 - $35.27 $17.2 Million - $33 Million
-934,799 Reduced 13.21%
6,139,064 $198 Million
Q4 2022

Feb 13, 2023

BUY
$18.32 - $30.66 $17.3 Million - $28.9 Million
942,047 Added 15.36%
7,073,863 $131 Million
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $6.41 Million - $12.7 Million
446,985 Added 7.86%
6,131,816 $166 Million
Q2 2022

Aug 12, 2022

BUY
$11.52 - $20.4 $4.58 Million - $8.11 Million
397,683 Added 7.52%
5,684,831 $78.6 Million
Q1 2022

May 12, 2022

SELL
$12.36 - $20.31 $580,314 - $953,574
-46,951 Reduced 0.88%
5,287,148 $103 Million
Q4 2021

Feb 10, 2022

SELL
$12.46 - $27.87 $465,605 - $1.04 Million
-37,368 Reduced 0.7%
5,334,099 $87.1 Million
Q3 2021

Nov 09, 2021

BUY
$25.78 - $33.21 $613,280 - $790,032
23,789 Added 0.44%
5,371,467 $150 Million
Q2 2021

Aug 11, 2021

BUY
$26.8 - $31.84 $143 Million - $170 Million
5,347,678 New
5,347,678 $159 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.